Clonotypic Peptide MS to monitor M-Protein reduction in Patients with relapsed/refractory MM from IKEMA study - ASH 2025

Monitoring minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) remains challenging due to invasiveness and limitations of bone marrow-based techniques such as next generation sequencing (NGS) or flow cytometry (NGF). In this abstract, the authors highlight the feasibility of deploying M-inSight^®, a minimally invasive, blood-based mass spectrometry assay, for long-term kinetic MRD monitoring in a large RRMM clinical trial.

M-inSight^® enabled highly sensitive M-protein quantification, with successful identification of baseline clonotypic peptides in 98% of patients, and supported longitudinal monitoring of treatment response. Importantly, the assay provided insights into remission and residual disease up to three years post-treatment, addressing a critical gap in long-term follow-up where bone marrow MRD assessments were often no longer performed. These findings highlight M-inSight^® as a powerful, patient-friendly solution for sustained disease monitoring without repeated bone marrow sampling.